Dylan Morris is a venture capital investor at Insight Partners who trained as a computational biologist before entering venture, building models of immune cells at the intersection of biochemistry, molecular biophysics, and computer science, which now directly informs how he evaluates and supports data-heavy biology companies. He leads Insight's dedicated bio practice with a software-first lens, focusing on computational biology and technology-enabled drug discovery rather than traditional wet-lab-only therapeutics investing, and describes himself as a biomedical accelerationist whose goal is to end involuntary dying, one disease at a time. Dylan Morris is a venture capital investor at Insight Partners who trained as a computational biologist before entering venture, building models of immune cells at the intersection of biochemistry, molecular biophysics, and computer science, which now directly informs how he evaluates and supports data-heavy biology companies. He leads Insight's dedicated bio practice with a software-first lens, focusing on computational biology and technology-enabled drug discovery rather than traditional wet-lab-only therapeutics investing, and describes himself as a biomedical accelerationist whose goal is to end involuntary dying, one disease at a time.